Meta-analysis finds no real difference in safety and effectiveness between tenofovir formulations
Depo Provera may worsen tenofovir-related bone loss in young women
Elevated fracture risk for people with HIV cannot be explained by changes in bone mineral density alone
96-week results of DISCOVER PrEP trial presented at European AIDS Conference
Switching from TDF to TAF associated with improvements in bone mineral density in people over 60
Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?
US study suggests that ageing people with HIV may have an increased risk of arthritis
Descovy is non-inferior to Truvada for daily PrEP
